See more : PT Radana Bhaskara Finance Tbk (HDFA.JK) Income Statement Analysis – Financial Results
Complete financial analysis of Entera Bio Ltd. (ENTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Entera Bio Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Tradelink Electronic Commerce Limited (0536.HK) Income Statement Analysis – Financial Results
- BiOptic Inc. (6850.TWO) Income Statement Analysis – Financial Results
- Allied Resources, Inc. (ALOD) Income Statement Analysis – Financial Results
- Casino, Guichard-Perrachon S.A. (0HB1.L) Income Statement Analysis – Financial Results
- Compute Health Acquisition Corp (CPUH-WT) Income Statement Analysis – Financial Results
Entera Bio Ltd. (ENTX)
About Entera Bio Ltd.
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 134.00K | 571.00K | 365.00K | 236.00K | 500.00K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 56.00K | 101.00K | 373.00K | 209.00K | 210.00K | 0.00 | 43.00K | 35.00K | 28.00K |
| Gross Profit | -56.00K | 33.00K | 198.00K | 156.00K | 26.00K | 500.00K | -43.00K | -35.00K | -28.00K |
| Gross Profit Ratio | 0.00% | 24.63% | 34.68% | 42.74% | 11.02% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 4.51M | 5.85M | 6.77M | 6.40M | 7.20M | 8.52M | 2.77M | 2.65M | 2.12M |
| General & Administrative | 4.43M | 7.25M | 5.69M | 4.89M | 4.28M | 2.84M | 8.58M | 2.72M | 1.59M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.43M | 7.25M | 5.69M | 4.89M | 4.28M | 2.84M | 8.58M | 2.72M | 1.59M |
| Other Expenses | 0.00 | -51.00K | -46.00K | 1.24M | 743.00K | 523.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 8.86M | 13.05M | 12.42M | 11.29M | 11.48M | 11.36M | 11.34M | 5.37M | 3.70M |
| Cost & Expenses | 8.86M | 13.15M | 12.79M | 11.50M | 11.69M | 11.36M | 11.34M | 5.37M | 3.70M |
| Interest Income | 31.00K | 83.00K | 0.00 | 28.00K | 84.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 29.00K | 28.00K | 84.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 56.00K | 64.00K | 53.00K | 63.00K | 238.00K | 54.00K | 43.00K | 35.00K | 28.00K |
| EBITDA | -8.80M | -12.87M | -12.16M | -11.11M | -11.35M | -10.81M | -11.05M | -5.33M | -3.67M |
| EBITDA Ratio | 0.00% | -9,714.18% | -2,130.30% | -3,050.14% | -4,752.54% | -2,161.40% | 0.00% | 0.00% | 0.00% |
| Operating Income | -8.89M | -13.02M | -12.22M | -11.13M | -11.45M | -10.86M | 11.34M | -5.37M | -3.70M |
| Operating Income Ratio | 0.00% | -9,714.18% | -2,139.58% | -3,050.14% | -4,853.39% | -2,172.20% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 31.00K | 134.00K | -29.00K | -28.00K | 659.00K | 557.00K | 146.00K | 4.17M | -581.00K |
| Income Before Tax | -8.86M | -12.93M | -12.25M | -9.96M | -10.80M | -10.30M | -11.20M | -1.20M | -4.28M |
| Income Before Tax Ratio | 0.00% | -9,652.24% | -2,144.66% | -2,729.59% | -4,574.15% | -2,060.80% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 29.00K | 137.00K | -59.00K | 20.00K | 84.00K | 557.00K | -146.00K | 0.00 | 0.00 |
| Net Income | -8.89M | -13.07M | -12.19M | -9.98M | -10.88M | -10.30M | -11.20M | -1.20M | -4.28M |
| Net Income Ratio | 0.00% | -9,754.48% | -2,134.33% | -2,735.07% | -4,609.75% | -2,060.80% | 0.00% | 0.00% | 0.00% |
| EPS | -0.31 | -0.45 | -0.47 | -0.54 | -0.90 | -1.30 | -1.31 | -0.14 | -0.36 |
| EPS Diluted | -0.31 | -0.45 | -0.47 | -0.54 | -0.90 | -1.29 | -0.94 | -0.10 | -0.36 |
| Weighted Avg Shares Out | 29.01M | 28.81M | 26.13M | 18.42M | 12.15M | 7.96M | 8.57M | 8.57M | 11.90M |
| Weighted Avg Shares Out (Dil) | 29.01M | 28.81M | 26.13M | 18.42M | 12.15M | 7.98M | 11.90M | 11.90M | 11.90M |
Entera Bio to Report Financial Results for the Year Ended December 31, 2020 on March 18, 2021
BOSTON and JERUSALEM, March 11, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report business and financial results for the year ended December 30, 2020...
Entera Bio Stock Skyrockets On Positive EB613 Biomarker Analysis Data In Osteoporosis Study
Entera Bio Ltd (NASDAQ: ENTX) is soaring in the premarket in reaction to positive topline data from the Phase 2 trial of EB613 in postmenopausal female subjects with osteoporosis (low bone mineral density). Three-month bone biomarker data analysis showed a significant increase in the...
ENTX Stock Price Increases Over 200% Pre-Market: Why It Happened
The stock price of Entera Bio Ltd. (NASDAQ: ENTX) has increased by over 200% pre-market.
Entera Bio Ltd Announces Positive Topline EB613 Phase 2 Biomarker Data
‒ Trial Met Primary Endpoint of Significant Increase in P1NP Based on Final Analysis of 3 Month Data ‒ ‒ Final Analysis of 6-Month Data , Including Change in Bone Mineral Density, Expected in Q2:21 ‒
Entera Bio Ltd. (ENTX) CEO Roger Garceau on Q3 2020 Results - Earnings Call Transcript
Entera Bio Ltd. (ENTX) CEO Roger Garceau on Q3 2020 Results - Earnings Call Transcript
Entera Bio Ltd Announces Third Quarter 2020 Financial Results and Provides Clinical Update
‒ Completed E nrollment in Phase 2 Clinical Trial of EB613, P ositioned as the F irst P otential O ral B one B uilding P roduct to T reat O steoporosis ‒ ‒ Positive Interim 6-Month Bone Mineral Density...
Entera Bio to Report Third Quarter 2020 Business and Financial Results on November 19, 2020
BOSTON JERUSALEM, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report business and financial results for the quarter ended September 30, 2020 on...
Entera Osteoporosis Trial, And Other News: The Good, Bad And Ugly Of Biopharma
Entera Bio reports encouraging data from osteoporosis trial. Alkermes progresses Phase 2 trial for ALKS 4230.
Entera Bio Ltd. (ENTX) Interim CEO Roger Garceau on Q2 2020 Results - Earnings Call Transcript
Entera Bio Ltd. (NASDAQ:ENTX) Q2 2020 Results Conference Call August 20, 2020 08:30 AM ET Company Participants Jon Lieber - U.S.
Head-To-Head Comparison: Seattle Genetics (NASDAQ:SGEN) vs. Entera Bio (NASDAQ:ENTX)
Seattle Genetics (NASDAQ:SGEN) and Entera Bio (NASDAQ:ENTX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk and institutional ownership. Profitability...
Source: https://incomestatements.info
Category: Stock Reports